In the future, it will be of great interest to utilize other surface-modification ligands to target various high-risk cancers, such as Lamp2b-VEGF for liver cancer, Lamp2b-EGFR for lung cancer, Lamp2b-RVG for neuron cancer and Lamp2b-MG7 for stomach cancer. This evidence concerns the gene VEGFA and liver cancer.